CERBA-RESEARCH
24.8.2021 14:03:02 CEST | Business Wire | Press release
Cerba Research , a leading global clinical trial laboratory services organization owned by Cerba HealthCare, announced today that they have joined forces with ACT Genomics under a joint venture model to create a purpose-built lab facility in Taiwan covering the Asia Pacific region.
This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
The expansion includes investments in a new facility in Taipei (Taiwan) and state-of-the-art technologies to strengthen capabilities and services offered to our clients on a truly global scale:
- Cutting-edge flow cytometry technologies
- Exploratory as well as In Vitro Diagnostic histopathology services
- Peripheral blood mononuclear cell (PBMC) isolations from blood and soft tissues
Progress on construction, technology transfers, and expansion of the scientific team will enable the CerbACT Asia Laboratory to be fully operational in September 2021.
Mario Papillon, CEO of Cerba Research comments: “This milestone with ACT Genomics validates our innovative history as a company. We will support our customers with the latest instrumentation and automation — backed by experienced scientists whose ambition and agility to meet patients’ needs drive our continuous evolution as a company.”
“We are excited to create a partnership with Cerba Research. Together, we offer a broader range of top-notch technologies and services in Asia. The formation of CerbACT Asia echoes our firm dedication in the well-being of cancer patients, keen commitment to society, and unequivocal embrace of precision medicine,” says Hua Chien Chen, CEO, ACT Genomics.
About Cerba Research
Cerba Research is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing early phase research, clinical development through central laboratory and diagnostic services, assay and biomarker development and validation. Working with government agencies, non-government organizations as well as pharma and biotech organizations to change the shape of clinical development. Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis.
About ACT Genomics
ACT Genomics is an innovation-driven cancer solution provider in Asia with offices in Taipei, Hong Kong, Singapore, Tokyo, and Wales (U.K.). With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team, and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we “Turn Genomics into Action.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005259/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
With More Than 2,000 Visitors, ATARASHII GAKKO! and Morimoto of Tontsukatan Lead the Opening-Day Countdown9.9.2026 03:07:00 CEST | Press release
Two New Projection Mapping Shows Featuring “OTONABLUE” and “TTTTOKYO” of ATARASHII GAKKO! Premiere The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907649202/en/ With More Than 2,000 Visitors, ATARASHII GAKKO! and Morimoto of Tontsukatan Lead the Opening-Day Countdown We are pleased to announce that two new projection mapping works featuring “OTONABLUE,” the signature song of ATARASHII GAKKO!, a four-member dance and vocal group active on the global stage, and their latest song, “TTTTOKYO,” began screening on Sunday, August 23. On opening day, a special event was held featuring ATARASHII GAKKO! and Morimoto of Tontsukatan as guests. Together
The Estée Lauder Companies Announces Expanded Roles for Brian Franz and Amber English8.9.2026 23:05:00 CEST | Press release
Appointments Support the Company's Ongoing Transformation Through Beauty Reimagined and Continued Focus on Consumer-Centric Growth The Estée Lauder Companies Inc. (NYSE: EL) today announced expanded leadership roles for two members of its Executive Team. Brian Franz has been appointed Chief Technology & Transformation Officer,expanding his responsibilities to include leading the company's enterprise-wide transformation. Amber English has been named President, Digital & Online, The Americas and Global Amazon Lead, assuming new enterprise-wide responsibility for The Estée Lauder Companies’ global relationship with Amazon. Both will continue to report directly to Stéphane de La Faverie, President and Chief Executive Officer, and remain members of The Estée Lauder Companies’ Executive Team. Both appointments are effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908417554/en/ Brian Franz, Chief Technology &
Samsung and Mistral AI Announce Strategic Partnership for Intelligence-Driven Semiconductor Infrastructure8.9.2026 18:15:00 CEST | Press release
Collaboration will focus on development and implementation of on-premises AI technologies across Samsung’s chip operationsSamsung makes lead investment in Mistral’s funding round Samsung Electronics Co., Ltd., today announced it has entered into a strategic partnership with Mistral AI to enhance its semiconductor engineering and manufacturing capabilities that will reinforce its leadership in AI chip technologies. The announcement of the partnership was made during the state summit held in Paris between South Korea and France. Under the agreement, Samsung will integrate Mistral’s AI services and solutions—including its flagship large language model, Mistral Large—across its semiconductor operations to develop customized on-premises AI models optimized for intelligence-driven infrastructure. Mistral’s powerful AI platform is expected to provide Samsung with a unique stack of tools that will transform how semiconductors are designed and manufactured. The on-premises enterprise solutions
Sensereo Airo Wins IFA Berlin Innovation Award8.9.2026 17:00:00 CEST | Press release
Prestigious Accolade Recognizes Sensereo’s Next-Generation Approach to Creating Healthier, Smarter Indoor Environments Sensereo, an environmental intelligence company developing next-generation sensing products for safer, healthier and smarter living, was presented with the prestigious IFA Berlin Innovation Award for its Airo modular indoor air quality system. The award was presented during IFA Berlin on Thursday, Sept. 4, recognizing Airo for its innovative approach to helping consumers better understand and manage the quality of their indoor environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260906292649/en/ Winner of a 2026 IFA Innovation Award, Airo is Sensereo’s flagship environmental intelligence platform, combining advanced sensing technology with a modular design that allows users to monitor multiple aspects of indoor air quality and environmental conditions through a single, consumer-friendly system. Desig
Verdantis Rebrands as the AI Super-Agent for MRO, Sets Sights on AI-Native Enterprise Asset Management8.9.2026 16:06:00 CEST | Press release
Nine AI agents now run the MRO decision chain for Fortune 500 plants; new tagline “Anticipate. Resolve. Learn.” Verdantis, the AI company for spare parts and MRO inventory optimization in asset-intensive industries, today unveiled its new brand identity as the AI Super-agent for MRO and announced it is building toward a fully AI-native Enterprise Asset Management (EAM) platform. Verdantis’s super-agent orchestrates nine specialized AI agents across the decisions that decide plant uptime: spare parts, criticality, demand, reorder, and work order planning. These decisions set working capital, maintenance spend, and whether a critical asset runs and, in most plants, they are still made in spreadsheets and disconnected systems. The positioning is for the teams who own uptime - maintenance, reliability, and MRO supply chain leaders in oil and gas, mining, utilities, chemicals, and manufacturing. And it reflects an AI-first architecture: agents decide and act by default; people supervise, ov
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom